News Sentiment

INBX sentiment intelligence

Inhibrx Biosciences, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 87.39 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

-6.0% over one week, -6.1% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act (NASDAQ:INBX)

Market Reaction

Price moving ahead of tone

68/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction -6.0% Price reacting lower
Trend fit Trend active -6.1% over four weeks
Fair value 115.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 31
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 7
TradingView 6
PR Newswire 4
Stock Traders Daily 3
simplywall.st 3
www.marketscreener.com 3
Sahm 3

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 13
Balance sheet 4
Regulatory and legal 4
Analyst action 3
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-58 of 58
Sahm Direct company coverage

How FDA’s Ozekibart BLA Acceptance for Chondrosarcoma Could Shape Inhibrx Biosciences (INBX) Investors

The FDA has accepted Inhibrx Biosciences' Biologics License Application for ozekibart to treat chondrosarcoma, setting a PDUFA date of April 14, 2027. This acceptance strengthens the regulatory timeline but highlights the company's single-asset concentration and ongoing losses. I

Tone
Positive 65/100
Event
Regulatory and legal
Published
15 Jun 2026 20:40
Source
Sahm
Stock Titan Direct company coverage

FDA accepts Inhibrx (NASDAQ: INBX) BLA for first chondrosarcoma therapy

The FDA has accepted Inhibrx Biosciences' Biologics License Application (BLA) for ozekibart (INBRX-109) to treat unresectable or metastatic conventional chondrosarcoma, setting a PDUFA goal date of April 14, 2027. This marks a significant milestone as ozekibart could become the f

Tone
Positive 73/100
Event
Market update
Published
15 Jun 2026 20:08
Source
Stock Titan
Investing.com Australia Direct company coverage

FDA accepts Inhibrx filing for rare bone cancer treatment By Investing.com

The FDA has accepted Inhibrx Biosciences' Biologics License Application for ozekibart, a treatment for unresectable or metastatic conventional chondrosarcoma, setting an April 14, 2027, goal date. Ozekibart, if approved, would be the first FDA-approved treatment for this rare bon

Tone
Positive 72/100
Event
Market update
Published
15 Jun 2026 18:08
Source
Investing.com Australia
PR Newswire Direct company coverage

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

Inhibrx Biosciences, Inc. announced that the U.S. FDA has accepted its Biologics License Application (BLA) for ozekibart (INBRX-109) to treat patients with unresectable or metastatic conventional chondrosarcoma. The FDA set a PDUFA goal date of April 14, 2027, with no identified

Tone
Positive 73/100
Event
Market update
Published
15 Jun 2026 13:39
Source
PR Newswire
Stock Titan Direct company coverage

Inhibrx Biosciences (INBX) director granted 15,000 stock options at $95.22

Inhibrx Biosciences director Douglas Forsyth was granted stock options for 15,000 shares of common stock at an exercise price of $95.22 per share. These options, which are a form of equity compensation, will become fully exercisable on June 3, 2027, provided Forsyth continues his

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 21:39
Source
Stock Titan